- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04117022
Diabetic Retinopathy Functional Evaluation Study: Monitoring Carotenoid Vitamins Treatment Using ERG
To evaluate the differences in retinal function as measured by ERG in diabetics with and without retinopathy 2) the ability of the Chromatic Electroretinogram (chERG) to detect changes in global retinal function following treatment with Carotenoid Vitamins supplement in patients with diabetic retinopathy (DR). 3) the ability of the Full Field flicker (ffERG) to detect changes in global retinal function following treatment with Carotenoid Vitamins supplement in patients with diabetic retinopathy (DR).
4) Changes in retinal function as observed by OCT-Angiography, following treatment with Carotenoid Vitamins supplement in patients with diabetic retinopathy (DR).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This prospective, study has cross-sectional analysis of ERG functions in a group of diabetics with and without retinopathy. Both Chromatic ERG and Full field ERG (NOVA, Diopsys, Inc. Pine Brook, NJ) will be utilized in the study. Subsequently individuals with an outside normal limit outcome on at least one ERG test will be invited to be part of the longitudinal study. Individuals with abnormal ERG results will be asked to take the carotenoid vitamin supplement (ZeaVision DVS supplement) and the baseline data will be compared to the values at one, three- and six-month follow-up.
The primary endpoint of a patient's follow-up will be at 6 months. The study will be performed at three sites. Western University of Health Sciences, Harpers Pointe Eye Associates (Externship site College of Optometry, Western University of Health Sciences) and Oklahoma College of Optometry, Northeastern State University, Tahlequah, Oklahoma.
The clinical study plan will be reviewed and approved by Eye Care Center of the Western University of Health Sciences Institutional Review Board (IRB). Harpers Pointe Eye Associates will be covered under an externship site of Western University of Health Sciences.
NSUOCO will apply for a separate IRB review at their own site.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Pinakin Davey, OD, PhD
- Phone Number: 909-469-8473 |
- Email: pdavey@westernu.edu
Study Contact Backup
- Name: Nathan Lighthizer, OD
- Phone Number: 918-444-4007
- Email: lighthiz@nsuok.edu
Study Locations
-
-
California
-
Pomona, California, United States, 91766
- Recruiting
- Western Universit5y of Health Sciences, College of Optometry
-
Contact:
- Pinakin G. Davey, OD, PhD
- Phone Number: 901-831-1562
- Email: contact@pinakin-gunvant.com
-
Contact:
- Ida Chung, OD, MSHE
- Phone Number: 909-469-8687
- Email: ichung@westernu.edu
-
-
Oklahoma
-
Tahlequah, Oklahoma, United States, 74464
- Recruiting
- Oklahoma College of Optometry, Northeastern State University
-
Contact:
- Nathan R. Lighthizer, OD
- Phone Number: 918-444-4007
- Email: lighthiz@nsuok.edu
-
Contact:
- Richard E. Castillo, OD
- Phone Number: (918) 444-4038
- Email: castillo@nsuok.edu
-
Principal Investigator:
- Pinakin Davey, OD, PhD
-
Principal Investigator:
- Nathan R. Lighhizer, OD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Age 21-80 years
- History of Diabetes for at least > 5years
No retinopathy, Mild or Moderate Non-Proliferative diabetic retinopathy
- Diabetes without retinopathy (Appendix A)
- Mild to moderate NPDR as defined by the American Academy of Ophthalmology7 (Appendix A)
Exclusion Criteria:
• History of any systemic or ophthalmic condition (other than diabetic retinopathy) capable of affecting vision
- Presence of Diabetic Macular Edema
- History of intraocular surgery, including macular or panretinal photocoagulation laser (except uncomplicated cataract or keratorefractive surgery more than 6 months prior to enrollment)
- History of treatment affecting vision, influencing reaction time and/or drugs indicating severe general diseases (eg. Hydroxychloroquine, tamoxifen, dexamethasone, triamcinolone, fluocinolone, etc.)
- Spherical refraction outside ±5.0 D or cylinder correction outside ±3.0 D
- Inability to obtain reliable Chromatic ERG test
- Pregnant and nursing women
- Allergy to the supplement or any of its ingredients
- Any subject that all ERG study tests or the OCT angiography cannot be obtained reliably.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: supplemented arm
Each subject will receive DVS formula, 2 softgels per day for 6 months.
|
Oral supplement.
Each subject will be given the carotenoid supplement of DVS formula.
The DVS formula consists of vitamins C, D3 and E (d-α tocopherol), zinc oxide, eicosapentaenoic acid, docosahexaenoic acid, α-lipoic acid (racemic mixture), coenzyme Q10, mixed tocotrienols/tocopherols, zeaxanthin, lutein, benfotiamine, N-acetyl cysteine, grape seed extract, resveratrol, turmeric root extract, green tea leaf, and Pycnogenol (patented French Maritime Pine Bark extract, sp Pinus pinaster, Horphag Research, Geneva, Switzerland).
Supplements bottles will be labelled with a unique identification number for each subject and supplied by ZeaVision, LLC, Chesterfield, Missouri, USA.
To assure that the participants do not have any issues with the vitamin supplement and to ensure adequate adherence to schedule of vitamin intake the participants will get regular phone calls from the study investigators (once every two weeks).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chromatic ERG (ChERG) Outcome Measurements: B wave and PhNR latency (milliseconds) Full field ERG outcome measurements and Chromatic ERG Outcome Measurements
Time Frame: Change from Baseline to 6 months
|
The Chromatic Electroretinogram (chERG) and the full field ERG will be recorded using a commercially available system Diopsys® NOVA (Diopsys, Inc.
Pine Brook, New Jersey).
The Red-Blue stimulus will be presented using a mini-Ganzfeld handheld device.
The entire process consists of two tests per eye, with twenty-five seconds allocated for each test; thus, the total duration of the test is one hundred seconds.
The chERG will be consecutively recorded from both eyes by means of proprietary adhesive skin electrodes on the lower eyelid and forehead.
|
Change from Baseline to 6 months
|
Full-field flicker ERG (ffERG) Measurements: magnitude (microvolts) and the phase (milliseconds) and the area ratio for magnitude and the area ratio for Phase
Time Frame: Change from Baseline to 6 months
|
The Flicker ERG will be recorded using a commercially available system, Diopsys® NOVA (Diopsys, Inc., Pine brook, NJ), version 2.19.19778.7332).
The Flicker ERG will be consecutively recorded from both eyes by means of adhesive skin electrodes on the lower eyelid and skin.
The stimulus will consist of white flashes flickering at 32 Hz over a white background as well as a sequence of 6 steps of increasing luminance.
|
Change from Baseline to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Macular pigment optical density (MPOD in relative density units)
Time Frame: Change from Baseline to 6 months
|
Subjects are asked to identify when they detect a flickering stimulus of varying intensity, allowing determination of relative density of xanthophyll macular pigments.
|
Change from Baseline to 6 months
|
Optical coherence tomography angiography (OCTA): radial macular and optic nerve capillary density (number/square millimeter)
Time Frame: Change from Baseline to 6 months
|
OCT angiography measurements will be performed using the Angiovue OCT by Optovue CA.
It is a camera system that utilizes interferometry to measure the thickness and vascular profile of the macula and the optic nerve, allowing measurement of radial capillary count in both macula and the peripapillary optic nerve head region
|
Change from Baseline to 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Nathan Lighthizer, OD, Northeastern State University, School of Optometry
- Principal Investigator: Pinakin Davey, OD, PhD, Western University of Health Sciences, College of Optometry
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-094
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
Clinical Trials on DVS supplementation
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedMenopauseBelgium, Finland, Sweden, South Africa, Croatia, United Kingdom, France, Romania, Ukraine, Spain, Poland, Hungary, Czech Republic, Mexico, Netherlands
-
Wyeth is now a wholly owned subsidiary of PfizerTerminated
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder | Depression | Major Depressive Disorder
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedHot Flashes | Menopause | Sleep Disorders
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedMajor Depressive Disorder
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedMajor Depressive Disorder
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedMajor Depressive Disorder
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedMajor Depressive Disorder
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedMajor Depressive Disorder
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVasomotor SymptomsUnited States